Malignant pleural mesothelioma (MPM) genomic profile in the randomized phase II RAMES Study.

M Pagano,R Gnoni,Candida Bonelli,Francesca Zanelli,Marina Chiara Garassino,Giovanni Luca Ceresoli,Giulia Pasello,Marcello Tiseo,Hector Soto Parra,Federica Grosso,Paolo Andrea Zucali,Federica Torricelli,Carmine Pinto

Malignant pleural mesothelioma (MPM) genomic profile in the randomized phase II RAMES Study.

2019

M Pagano
R Gnoni
Candida Bonelli
Francesca Zanelli
Marina Chiara Garassino
Giovanni Luca Ceresoli
Giulia Pasello
Marcello Tiseo
Hector Soto Parra
Federica Grosso
Paolo Andrea Zucali
Federica Torricelli
Carmine Pinto

8547Background: Since MPM is an uncommon neoplasia, its rarity has limited available data on molecular drivers. Methods: RAMES study evaluated the second-line efficacy of gemcitabine/ramucirumab tr...

Keywords:

Mesothelioma
Pathology
Oncology
Ramucirumab
Genomic Profile
Gemcitabine
Medicine
Internal medicine
pleural mesothelioma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations